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ABSTRACT 
 
Acute inflammation is a natural biological defensive response against infection, 
irritation, and injury.  While inflammation is a natural process, chronic tissue 
inflammation has been implicated in the development of several different diseases.  With 
the intent of minimizing collateral damage associated with long-term exposure of healthy 
tissues to anti-inflammatory drugs, the Pedigo laboratory has designed a system for the 
self-assembly of protein polymers as scaffolds for controlled-release of drugs to affected 
tissues.  This protein polymer comprises two essential components, with the first 
component being the calcium-dependent protein, calmodulin, and the second being a 
corresponding binding peptide, M13.  Because Calmodulin has a specific, high affinity 
for the M13 peptide, and because the human body has an inherently high concentration of 
extracellular calcium, we expect that the two polymers will interact in a calcium-
dependent manner forming a supramolecular polymeric matrix.  This protein-based 
matrix will be covalently modified with anti-inflamatory agents like asprin or ibuprofen.  
Assembling this system at the site of chronic inflammation will allow for the controlled 
in situ delivery of medication, which would in turn significantly reduce dosage and 
eliminate the adverse effects accompanying systemic delivery of medications.  An 
essential component of this nascent research is determining the toxicity of the protein 
scaffold. Through collaboration with Dr. Shabana Khan in the Natural Products Center, 
made possible by funding from the Sally McDonnell Barksdale Honors College, access to 
state of the art cell toxicity assays and several different cell lines has been made available 
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for testing. The objective of this thesis is to perform cytotoxicity tests to demonstrate the 
viability of human cell lines when co-cultured with the self-assembling peptides, peptide 
derivatives, and peptide-polymer conjugates that compose the self-assembling 
biomaterial.  This research is the first step for the foundation of further investigation into 
the in vivo safety of the biomaterials under development.   
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CHAPTER 1 
OBJECTIVES 
The goal of our laboratory is to create a protein-scaffold based biomaterial for in situ 
drug delivery.  This material requires that two protomers of our design interact in vivo to 
create a the scaffold. These protomers will be covalently modified with drugs.  Once 
assembled into a matrix, they will serve as a drug depot that will slowly release drug at 
the sight of inflammation, for example.  The purpose of the work reported in this 
document is to establish early in the development of the protein-based scaffold whether 
the scaffold itself is toxic to mammalian cells.  The development of this assay is 
investigated in the following four objectives. 
Objective 1 
The first step is the verification of correctly constructed protein and peptide 
biomaterials.  Protein and peptide polymers seen in Figure 1 are to be constructed in the 
Pedigo laboratory following the respective protocol for each.  
 
 
 
Figure 1: Schematic of design for the M13 and CaM biomaterials
The M13 and CaM biomaterials are designed in such a way that when taken up in 
an increased Ca2+ solution, interactions between the protein and peptides will cause the 
formation of a matrix-like scaffold.  The CaM and M13 interaction is the junction point 
between the polymers that are formed, as seen in Figure 2.   
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Figure 2: Calcium induces matrix formation 
Objective 2 
Once the biomaterials have been constructed, multiple cell lines must be cultured for 
testing.  This requires collaboration with Dr. Shabana Khan and her team of scientists that 
have several different cell lines used for testing various materials.  While there are 
various different cell lines available for testing, choosing the correct one for testing of our 
biomaterials is crucial.  Two different critical tissues in the body that are particularly 
vulnerable are the kidney and the liver.  Due to their normal physiological functions in 
filtration and processing of diverse materials, they are exposed to exogenous chemicals 
and must be metabolically active. Therefore, since they are the most vulnerable, they are 
also the most important to study in this toxicity assay. Through discussion with Dr. Khan 
and her team, liver and kidney cell lines have been chosen for testing. 
Objective 3 
In order to test the biomaterials, they must be co-cultured with cells for a period of 
time and then tested for toxicity with an MTT assay.  The MTT assay materials and 
protocol have been made available through collaboration with Claire Tran-Tran, a 
researcher in the Khan Laboratories.  This assay will test for cell activity after introduced 
to the biomaterials for differing time periods.   
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Objective 4 
The final step is to interpret the results from the assays and to determine levels of 
toxicity and viability of the human cells after exposure to the biomaterials.  CaM and 
M13 are normally intracellular proteins.  However, our constructed protein and peptide 
will not affect normal intracellular function of CaM and its physiological targets that it 
normally regulates.  Instead, our materials assemble and function in the extracellular 
space; therefore, it is important to study the effects of these biomaterials on the cells from 
an extracellular standpoint.   
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CHAPTER 2 
INTRODUCTION TO BIOMATERIALS 
Calmodulin 
Calmodulin is an essential component of one of the two unique protein polymers that 
will be developed and used in the assembly of the biomaterial scaffold.  The fundamental 
aim of this research project as a whole is to exploit several ideal characteristics of 
Calmodulin that will allow for the self-assembly of a supramolecular polymeric network 
for the intended use of in situ drug delivery. 
Firstly, one of the main benefits to calmodulin is that it is a 148 residue, acidic 
intracellular protein that is one of the most well studied proteins of the last 30 years [1].  
Another distinct advantage of calmodulin lies in its extreme sensitivity to calcium 
concentrations.  The Kd for calcium binding to calmodulin is ~1 µM in the C-terminal 
sites and ~10 µM in the N-terminal sites [2].  This evidently shows that both ends of the 
calmodulin protein bind calcium with a relatively high affinity, as seen in Figure 3.   
 
 
 
 
Figure 3: Ribbon diagram of CaM saturated with Ca2+ at all four binding sites [3, 4]. 
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To prove the point of calcium sensitivity even further, calmodulin also functions as 
the calcium-sensitive regulatory unit for a number of signal transduction pathways [1].  It 
is the high affinity, calcium dependent association with these binding partners that makes 
calmodulin so crucial to this study is the biological functions of recognition and 
regulation of other protein molecules [5].   
Calmodulin is an intracellular Ca2+ receptor protein which regulates a variety of 
cellular enzymes and processes including cyclic nucleotide phosphodiesterase, adenylate 
cyclase, phospholipase A2, Ca2+-ATPase, phosphorylase kinase, neurotransmitter release, 
phosphorylation of membranes, the disassembly of microtubules, and Ca2+ transport [6].  
Because alterations in cellular Ca2+ fluxes have been implicated to be involved in steps 
leading to irreversible cell damage [6], and because calmodulin participates in the 
regulation of the flux of calcium within cells, the relationship between toxicity and 
alterations of calcium and calmodulin levels must be explored [6].  While inhibition of 
calcium uptake and inhibition of calmodulin function can prove deadly within cells, the 
calmodulin biomaterials in this research project are not intended for intracellular use.  
The biomaterial will be injected under the skin and be surrounded by cells, but the 
biomaterial matrix itself will be outside of the cells.  Even though CaM is a natural and 
essential intracellular protein, it may induce a response when found within the 
extracellular space.  That is what this assay is intended to study, is the effect of the 
biomaterials on the cells in an extracellular environment. 
Binding Peptide 
There are several different calmodulin-binding peptides that demonstrate differing 
degrees of binding affinities to calmodulin.  One of the most well studied binding 
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partners is the peptide from skeletal muscle myosin light chain kinase called M13 [7].  It 
has also been demonstrated that CaM has the ability to bind peptide substrates, such as 
M13, via hydrophobic pockets within each domain [8].  This partner was chosen due to 
the depth of literature that has dissected the importance of specific non-covalent forces in 
stabilizing the M13-CaM interaction.  What is so interesting about the peptide-binding 
partner is that we have the ability to change the sequence in order to control the binding 
affinity for CaM [9]; and the binding affinities for peptides to saturated calmodulin vary 
from 0.3 nM [5] to 70nM [10].  Given that the M13-CaM interactions are primarily 
hydrophobic interactions [8], their association constant is independent of pH [11], but 
dependent upon the placement of hydrophobic residues [12].  Thus, based on a long 
history of investigation we have the ability to specifically tune the interactions between 
CaM and M13 to optimize scaffold assembly and stability. 
Early structural studies involving NMR and X-ray crystallography have also 
demonstrated that M13, which is normally disordered, becomes helical, and CaM 
becomes more compact upon binding [13]. When introduced in solution along with 
calcium, the protein and peptide will come together to form a collagen-like matrix that 
will be the biomaterial used for the in situ drug delivery. Our current studies will consider 
only the use of the wild-type peptide.  This wild-type peptide consists of 26 residues, as 
seen in Figure 4.			
  
Figure	4.	The	amino	acid	sequence	of	M13	peptide				
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Protein and Peptide Matrix 
We seek to develop two protein-based alternating polymers that incorporate either 
CaM or M13 peptide as structural units, thereby exploiting the natural calcium-dependent 
binding of CaM and the peptide M13 as a mechanism for self-assembly of the proposed 
biomaterial, as seen in Figure 2.  The protein and peptide will come together to form a 
polymeric matrix that is stabilized through a network of noncovalent interactions.  The 
CaM- based polymer will consist of alternating CaM and ‘collagen-like’ structural units.  
We will refer to these polymers as CaM-collagenlike polymers, or CCLPs.  Conversely, 
the peptide-based polymers will consist of alternating M13 peptide and collagen-like 
sequences, which will be termed peptide-collagenlike polymers, or PCLPs.  What is 
unique about these collagen-like sequences is that they have been chosen for their natural 
ability to degrade because they are cleavage sites for matrix metalloproteinases, also 
known as MMPs (and collagenases).  The MMP-cleavable sequences have been 
extensively noted for their application in creating biodegradable hydrogels [14-17].  
While constructing these collagen-like sequences, we have incorporated three repeating 
type I collagen-derived MMP cleavable sequences, GPQG/IWGQ, into the CaM and 
M13-based protein polymers.  These collagen-derived sequences are also interspaced by 
the pentapeptide sequence GSGYG that serve the purpose of a functionalization site for 
the attachment of drugs (-OH groups on the side chains of Serine (S) and Tyrosine (Y)).  
Through exploitation of calcium concentration in the extracellular space, which 
strengthens the interactions between M13 peptide and calmodulin, the spacer-peptide and 
spacer-calmodulin alternating copolymers will assemble into a matrix in vivo in the EC 
space [18].  Thus, upon assembling into the 3D matrix in the presences of Ca2+, the 
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biomaterial will also be capable of biodegradation through the MMPs so that the matrix is 
labile during inflammation, which is the intended use for the biomaterial.  
18	
 
 
 
CHAPTER 3 
EXPERIMENTAL APPROACH 
This section describes the two iterations of the toxicity assay that were performed. 
The first experiment, the Intermediate Toxicity Assay,  observed the effect of CaM and 
M13 materials over a maximum of 8 hours of cell growth.  The second experiment, the 
Long-term Toxicity Assay, observed the effect of CaM and M13 materials over a 24 hour 
period.  All details of the experiment are discussed below. 
Intermediate Toxicity Study 
The immediate toxicity study was the first of two tests conducted on the biomaterials 
in order to determine the viability of cells when directly introduced to CaM and M13 
materials.  In this experiment, non-serum medium and a single cell line was to be used.  
This provides the opportunity for the biomaterials to be the only thing that affects cell 
viability.  Therefore, the cells were washed in non-serum medium and directly exposed to 
the biomaterials for four, six and eight hours as a foundational experiment to inform the 
Long-term Toxicity Assay. 
Long-Term Toxicity Study 
While the purpose of the intermediate study was to gain an immediate understanding 
of the effect of the biomaterials on the cells, the aim of the long-term study is slightly 
different. The long-term study was conducted over 24 hours to determine the toxicity of 
the biomaterials that were exposed to live cells contained in serum medium for a longer 
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period of time.  As such, this experiment differes from the Intermediate Toxicity Assay in 
two ways: the time frame is 3x longer and there is protein in the medium along with our 
test materials.  This second assay provides a more accurate representation of how the 
cells will respond to foreign biomaterials in vivo.  Two different cell lines are also to be 
used in this experiment.   
INTRODUCTION TO CYTOTOXICITY TESTING 
Since the proposed research materials will be released inside the human body, it is 
essential that the protein-based polymers are assessed for cytotoxicity, and mammalian 
cells are tested for viability upon exposure to the biomaterials.  Given the fact that 
cytotoxic experiments are more biological in nature, collaboration with other departments 
with access to expertise, equipment, and appropriate materials was established.  Dr. 
Shabana Khan, a principal scientist in the Natural Products Research Center, served as 
my direct mentor for these studies, granted me access to her lab, and provided me 
guidance for all aspects of the toxicity assays.  There are several different assays that are 
based upon various cell functions such as enzyme activity, cell membrane permeability, 
cell adherence, ATP production, co-enzyme production, and nucleotide uptake activity 
[19].  The route in which I will gauge the cytotoxicity of the biomaterials is through the 
means of cell viability and cytotoxicity assays, which are used for drug screening and 
cytotoxicity tests of chemicals [19].  The assay that is used in this experiment is the MTT  
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction 
assay.   
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Theory of Cytotoxicity Testing 
 In order to determine the viability of the cells and toxicity levels of the protein 
and peptide biomaterial a cell viability assay was performed.  Cell viability and 
cytotoxicity assays are used for drug screening and cytotoxicity tests of chemicals [19].  
There are various reagents that are used for cell viability detection, and they are all based 
upon various cell functions such as enzyme activity, cell membrane permeability, cell 
adherence, ATP production, co-enzyme production, and nucleotide uptake activity [19].  
The different various reagent used in cytotoxicity assays can be seen in in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Schematic of different cell viability assays and associated dyes. (Figure taken 
from [19].) 
 
Figure 5 demonstrates the different avenues that can be exploited when testing for 
cytotoxicity.  Some of these are more advanced techniques that are expensive and more 
along the lines of antigenicity, while I am assessing solely toxicity. The best and most 
cost-efficient assays for determining cell toxicity are enzyme-based methods, such as 
MTT and WST-8.  These methods are easy-to-use, safe, and have a high reproducibility 
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[19]. The MTT technique, labeled as A in the MTT formazan dyes are based upon a 
colorimetric method and are best known for determining mitochondrial dehydrogenase 
activity within living cells [19].  The luciferase (bioluminescence) method, labeled as B, 
is an ATP detection reagent that contains a detergent that is used to lyse the cells and 
measure the amount of ATP that is released from the lysed cells [20].  While this assay is 
the fastest and most sensitive assay to use, it was not ideal for our experiment, as we wish 
to keep the cells alive and monitor them for as long as possible.  Another possible choice 
was the radioactively labeled thymidine approach.  In the Tritium-labeled thymidine 
uptake method, labeled as C, [3H]-thymidine is involved in the cell nucleus due to the 
cell growth, and the amount of the tritium in the nucleus is then measured using a 
scintillation counter.  While this approach is sensitive to determine the influence on the 
DNA polymerization activity, it requires use of a radioisotope which raises the problem 
of laboratory and environmental safety [19].    
Cell-based assays are often used for screening collections of compounds to determine 
if the test molecules have effects on cell proliferation or to show direct cytotoxic effects 
that eventually lead to cell death [20].  These methods allow for the researcher to estimate 
the number of viable cells after exposure to the materials that are under study.  
Regardless of the type of cell-based assay used, it is important to know how many viable 
cells are remaining at the end of the experiment [20].  In order to determine the toxic 
effect of the test materials, negative and positive controls must be run.  In these 
experiments negative control means that the cells survived, so conditions are such that the 
cells should grow, and growth is monitored over the same timeframe as the growth of the 
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cells in test materials.  The positive control is the addition of ethanol, and agent that kills 
the cells.  Thus, “positive” means that the growth was suppressed; the cells died. 
While there are a variety of assay methods that can be used to estimate the number of 
viable eukaryotic cells, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) tetrazolium reduction assay technology has been widely adopted and remains 
popular in academic labs as evidenced by thousands of published articles [20].  MTT falls 
under the category of an enzyme-based method.  These types of methods rely on 
reductive coloring reagents, as well as the active dehydrogenase activity within viable 
cells, in order to determine the cell viability via a colorimetric method [19].  The MTT 
assay is well known and the most widely used method for determining the mitochondrial 
dehydrogenase activity within living cells.  In this assay, MTT is a positively charged 
compound, and can therefore readily penetrate viable cells.  The NADH that is produced 
within the mitochondria of a living cell acts as an oxidizing agent to reduce the MTT, 
thereby forming purple needle-shaped crystals within the cells (Figure 6) [19].  
 
 
 
 
 
 
Figure 6: Reduction of MTT to Formazan. (Figure taken from [19].) 
Figure 6 illustrates how the NADH within the mitochondria of a living organism 
causes the reduction of nitrogen within the structure of MTT, producing the formazan 
product.  The exact cellular mechanism of MTT reduction into formazan is not well 
understood; however, the reaction most likely involves interaction with a reducing 
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molecule, such as NADH, that transfers electrons to MTT [21].  Despite broad 
acceptance of this assay, neither the subcellular localization, nor the biochemical events 
involved in MTT reduction are known [22].  The MTT dye is yellow, and once reduced 
into formazan, it turns purple.   
This formazan product of the MTT tetrazolium accumulates as a precipitate 
within the cell, as well as being deposited near the cell surface and in the culture medium 
[23-25].  Before absorbance readings can be taken, the formazan must be solubilized.  
There are a variety of different methods used to stabilize the formazan product, but the 
method that I used was solubilization with DMSO.  The DMSO used in this experiment is 
crucial, as it solubilizes the reagent and promotes its transfer through the cell membrane 
so that it is uniformly distributed theough the overlaying liquid.  Once the formazan has 
been solubilized, the plate can then be read.  While the MTT assay is an extremely easy 
and efficient method in determining toxicity, it also has a few limiting factors as well.  
One limitation is that the amount of signal that is generated when the plate is read is 
dependent upon several parameters.  These include: the concentration of MTT within 
each well, the length of the incubation period, the number of viable cells within each 
well, and the metabolic activity of the cells.  The last parameter is especially important, 
because when the cells die, they lose the ability to convert MTT into formazan [20].   
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CHAPTER 4 
MATERIALS AND METHODS 
Media and Buffers 
RMPI media (Roswell Memorial Park Institute) is a growth media for cells. It 
contains a carbonate/HEPES pH buffer system with vitamins, glucose, and amino acids 
added.  The RPMI medium is used to culture the PK1 cell line.  DMEM is the growth 
media used for the HepG2 cells. Its full name is Dulbecco’s Modified Eagle’s Medium 
and contains 4500 mg/L glucose and sodium bicarbonate, without L-glutamine and 
sodium pyruvate, liquid, and is sterile-filtered. 
Cell Lines 
The choice of an appropriate cell line for this study proved to be a very important 
task, as there are several different perpetual cell lines that cultured in Dr. Khan’s lab.  
Through the guidance and direction of Dr. Khan, it was made clear to me that testing our 
materials on human cell lines made the most sense, as the drugs are eventually intended 
for use on mammals.  The next step was to determine which types of cells would be most 
viable for study.  While cancerous cell lines were a viable option, Dr. Khan and I thought 
that it would be most efficient to test the materials on normal, healthy mammalian tissue.  
Therefore, the two cell lines that were chosen were pig kidney and human liver cell lines 
(LLC-PK1 and HepG2).  The cell lines were obtained from ATCC (Manassas, VA; 
www.atcc.org).  one of the cell lines chosen was a cancerous mammalian cell line, while 
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the other was a normal, healthy mammalian cell line.  Dr. Khan and her research team 
sub-culture all of their cell lines on a weekly basis.  From the cultures of cells that her 
research team had, I was given my own two cell lines to sub-culture.  Using aseptic 
techniques, I followed a protocol to sub-culture the cells and seed the plates with the cell 
lines for testing.   
HEPG2 
HepG2 is one of the perpetual cell lines used in this research.  HepG2 is a human 
liver carcinoma cell line derived from the liver tissue of a 15-year-old Caucasian male 
(Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7: HepG2 cells underneath a microscope shown growing to the correct 
confluency.[26] 
 
Since HepG2 cells are from liver epithelial cells, they secrete many plasma 
proteins, such as transferring, fibrinogen, plasminogen and albumin.  These cells are 
adherent and epithelial-like in nature, as they grow in monolayers and in small 
aggregates.  HEPG2 cells are grown in a buffer medium called DMEM.  This medium 
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contains no proteins, lipids, or growth factors.  This is perfect for my experiment because 
the concentrations of the proteins and peptides that I am testing in this experiment are 
very small. In order to minimize the interactions of the proteins and other particles in the 
buffer medium, the DMEM was not supplemented with serum, such as 10% Fetal Bovine 
Serum (FBS). This allows for only our protein and peptide to come into contact with the 
cells and keeps the proteins in the medium from interfering with the materials that are 
being tested.  This non-serum medium doesn’t allow for the cells to grow, so the 
experiment had to be carried out in a timely manner in order for the cells to be tested 
while they were still alive.  This is why the experiment only lasted for the duration of 
eight hours, rather than a few days like some other MTT assays run.   
LLC-PK1 cell line 
The LLC-PK1 cell line was derived from the kidney of a normal, healthy male pig 
that was between 3 and 4 weeks of age (Figure 8). [27] 
 
 
 
 
 
 
 
 
 
Figure 8: LLC-PK1 epithelial cells under a microscope shown grown to confluence [27]. 
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The LLC-PK1 line, like the HEPG2 cell line, also exhibits typical epithelial 
morphology and is often used as a model for epithelial tissue, as well as in a wide 
spectrum of pharmacologic and metabolic research investigations.  The buffer used to 
grow the PK1 cell line is an RPMI buffer.  The RPMI medium is unique from other 
medium as it contains the reducing agent glutathione and high concentrations of vitamins, 
such as inositol and choline, which are present in very high concentrations.  
Cell Toxicity Protocol 
Overview of Cell Preparation  
A major parameter of this experiment is making sure that each cell within the 96 well 
plate is seeded to the correct density of 5,000 cells per well.  This means that the cells 
must be taken from their liquid culture and counted to ensure that all wells contain the 
same number of cells.  If the cell count for each well is not the same, then the data could 
be skewed.  Therefore, the cells from each cell line are grown in a liquid culture to a 
specific density.  This density is then read with a cell counter and correctly aliquoted into 
each well and grown to the proper confluency.   
Day 1: Prepare the Cells  
Cell Count 
In order to make sure there are 5,000 cells in each well of the three 96 well plates, a 
cell count was done on the cell suspension using the Bio-rad TC20TM automated cell 
counter.  The sample of cells were loaded onto a slide and inserted into the cell counter.  
The TC20 cell counter then performed an auto-calibration process that calibrates the 
machine to the specific cell line under study.  The TC20 automated cell counter then 
counted the mammalian cells in one simple step using its auto-focus technology and 
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sophisticated cell counting algorithm.  This process is repeated twice, and the average is 
taken of the two readings to determine the average number of cells contained within the 
cellular suspension.  While this process is not completely accurate, it is the most 
advanced process available to estimate the cell count for cultured cells.  
Seeding the plates 
The following formula was used to determine the appropriate volume needed to plate 
the cells at 5,000 cells in each 96 well plate: (D1)*(V1) = (D2)*(V2).  D1 is the density of 
the cells, which is the cell count, D2 is the desired cell count, V2 is the final volume, and 
V1 is the start volume.  V1 was the unknown and the volume needed in order to determine 
how much of the cell suspension to add to the DMEM media in order to have enough 
volume to seed three 96 well plates.  At this point, 100 µL of cells were added into each 
well using a multi-channel pipet man.  The plates were then placed in the incubator at 
37oC and 5% CO2 for 24 hours in order to grow the cells to the proper confluence. 
Day 2: Treatment of cells with biomaterials 
The CaM protein started out at a stock concentration of 100µM and the M13 peptide 
at a stock concentration of 50µM.  The biomaterials for the intermediate toxicity study 
were junction constructs of protein and peptide material.  The biomaterials in this 
experiment were CaM and M13, but they were not the constructs that are laid out in 
Figure 1.  In the subsequent long-term toxicity study, the CCLP construct mentioned in 
Figure 1 was then tested.  Prepping the materials requires a serial dilution in order to get 
both the protein and peptide to the same working concentrations to be used during 
testing. (Fig 9, 10)  
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Figure 9: Serial dilution scheme for protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Serial dilution scheme for peptide 
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In this experiment, as mentioned above, two different controls were used.  The 
positive control was 100% ethanol, which should kill all of the cells.  The negative 
control was HEPES buffer, which is the buffer in the stock concentration of protein and 
peptide. The wells of the plates in the intermediate and long-term toxicity studies were 
exposed to our biomaterials and control components according to the schematic in Table 
1.  The plates were then left to incubate for their respective time periods  
Intermediate 
 
Long-Term 
 
Table 1: Testing concentration of the biomaterials in the intermediate and long-term 
toxicity assay respectively 
 
MTT assay protocol 
 All the media was carefully removed from each well of the 96 well plate via pipet 
tip attached to a hose and suction nozzle. The MTT stocking solution was then prepared, 
which is 5 mg of MTT in 1 mL of PBS.  The MTT working solution was prepared, which 
is a 1:10 dilution of MTT stocking solution into non-serum media.  Next, 100 uL of MTT 
  protein peptide control 
HEPG2  
2µM 0.2µM 0.02µM 2µM 0.2µM 0.02µM 
(+)2µM (+)0.2µM (+)0.02µM 
1st rep (+)2µM (+)0.2µM (+)0.02µM 
2nd rep (-)2µM (-)0.2µM (-)0.02µM 
3rd rep (-)2µM (-)0.2µM (-)0.02µM 
PK  (+)2µM (+)0.2µM (+)0.02µM 
1st rep (+)2µM (+)0.2µM (+)0.02µM 
2nd rep (-)2µM (-)0.2µM (-)0.02µM 
3rd rep (-)2µM (-)0.2µM (-)0.02µM 	
Protein	 Peptide	 Control	
2μM	 0.2μM	 0.02μM	 2μM	 0.2μM	 0.02μM	 (+)2μM	 (+)0.2μM	 (+)0.02μM	
2μM	 0.2μM	 0.02μM	 2μM	 0.2μM	 0.02μM	 (-)2μM	 (-)0.2μM	 (-)0.02μM		
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working solution was added into each well.  Several wells were left as control with media 
and no added MTT.   The plates were then allowed to incubate for two hours to allow for 
the MTT to be taken up and reduced by the cells.  After the incubation period, the plate 
was then shaken lightly on a rotating plate shaker for two minutes.  Afterwards, all media 
was removed and 200 uL DMSO was added to each well in order to dissolve the 
formazan crystals.  The plate was then read at 570 nm using a microplate reader.[28] 
  
32	
 
 
 
CHAPTER 5 
RESULTS 
Data Processing 
The cellular viability in each well was measured by UV-Vis spectroscopy with the 
micro plate reader.   The results from the experiment were values ranging from 0 to 
around 0.3; Zero was the value for no growth (ethanol control) and 0.3 was the highest 
value for the cells that grew.  In order to determine the average amount of growth for the 
respective concentrations, 2 µM, 0.2µM, and 0.02 µM, a few calculations were 
performed.  Firstly, the average growth contained in the negative control wells was taken.  
The negative control is a buffer solution that allows for normal cellular growth; therefore, 
it is the control to which all growth data were compared.  Second, the average was taken 
of the numbers for each respective biomaterial concentration.  As an example, the 
intermediate toxicity study only had an average of two wells, while the long-term study 
had an average of four wells.  Lastly, the average of each protein and peptide 
concentration was divided by the average concentration of the negative control and 
multiplied by 100.  We first did an assessment of the trends in cell growth as a function 
of time by simple comparison of the controls (Table 2).  The relative growth values for 
the Calmodulin and M13-peptide samples are plotted in the bar graphs in Figure 11, and 
12.  The error bars are the standard deviation in the average.   
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To assess whether cell were killed by ethanol (positive control), we compared the 
background absorbance of the a empty well to the ethanol added cells.  They were 
identical to the third decimal places (~0.100 AU) with the exception of the 6 hour time 
point (Table 2; discussed below).  Next we compared this value to that for negative 
control (added buffer) for the 4, 6 and 8 hour time points.  At each time point the growth 
in the negative samples exceeded the positive control, as we would have predicted.  This 
difference means that cells in the Live Well samples were growing.  The difference 
between the Live Well and Positive control values led to an estimate of the growth of 
cells as a function of incubation time.  Notice that the signal from MTT approximately 
doubled every two hours of incubation (starting at the 4 hour time point).  
Comparison of the Controls 
Hours Dead/Empty(+) Live Well(-) Difference 
4 0.100±0.012 0.125±0.002 0.025±0.012 
6 0.132±0.008 0.198±0 0.066±0.008 
8 0.109±0.007 0.187±0.077 1.013±0.077 
 
Table 2: Calculations of the average growth with standard deviations of the positive and 
negative control wells. 
 
Regarding the 6-hour time point, the absorbance reading for both the positive control 
and the Live Well samples exceeds the other time points, but the difference between them 
shows growth in an intermediate range.  This fact indicates that these data are elevated by 
some extraneous factor, like a plate that was scarred or otherwise had a partially 
obstructed optical surface. 
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Figure 11: Results from the intermediate toxicity study with standard deviation bars (I) 
included to show the differences in growth between the samples.   
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Intermediate Toxicity Assay 
Results from the intermediate toxicity study can be seen in Figure 11.  This figure 
shows the results from the three different plates that were under study.  The preliminary 
test data from the intermediate cytotoxicity assay shows that the protein (CaM) and 
peptide (M13) from the four hour study, at 2 µM, 0.2µM, and 0.02 µM concentrations, 
are not toxic to the HEPG2 cells.  Based upon the data from the assay, the protein and 
peptide actually promote cellular growth in the cell cultures at the 4 hour time point, 
which is a normal response to cells being treated with a protein source. In the six hour 
study, the results are inconsistent.  Eventhough there is more overall growth, there is no 
systematic trend as a function of the concentration of added protein or peptide. At 8 
hours, growth in the presence of added protein or peptide is indistinguishable from the 
negative control (growth in buffer only).  In conclusion there was a short term effect of 
added Calmodulin protein or M13-peptide, but no longterm effect. 
Long-term cytotoxicity study 
The second part of the objective 3 in this research plan was to perform a study that 
would demonstrate the viability of cells over a longer period of time.  While the 
intermediate toxicity test allowed for controlled and quick assessment of cell viability, 
incubation of cells with the biomaterials for a longer period of time will simulate the 
exposure of the protein and peptide in vivo within the human body.  Also, since there was 
no seum in the intermediate toxicity study, growth may be limited by the availability of 
protein as a food source. Another distinct difference in the long-term study from the 
intermediate study was the testing of the CCLP construct.  The CaM used in the 
intermediate study was isolated calmodulin, not the construct shown in Figure 1.  
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However, the CaM used in the long-term study was in fact the construct that is seen in 
Figure 1, the actual construct that will be used to created the biomaterials at a later time.  
Additionally, another distinct difference is that two different cell lines were used in this 
experiment.  The cell line LLC-PK1 was studied in conjunction with HEPG2. The results 
from the 24-hour study can be found below in Figure 12. 
The results from this experiment correlate directly with the results from the 
intermediate toxicity experiments and show that the protein and peptide actually enhance 
the growth of the cells.  Both the protein and peptide seem to act in a food-like manner 
for the cells to feed off of instead of actually inhibiting growth at the cellular level.  
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Figure 12: Results from the 24-hour plate with standard deviation bars (I) showing 
enhanced growth of both cell lines.  (Top: both cell lines, Middle and bottom: Individual 
cell lines) 
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DISCUSSION 
Trends in Intermediate Toxicity Study 
Controls: The results showed that at four and eight hours the positive control 
wells had almost identical readings and were normalized against the testing 
concentrations with low error.  However, at the six-hour mark, there was a larger amount 
of growth in the positive control wells for no apparent reason.  The positive control 
should kill all cellular growth at a constant and measurable difference.  Furthermore, 
from analyzing the difference between the dead and live wells, it is evident that there is a 
doubling in growth every two hours between the positive and negative control wells.  
This indicates that there is essentially a linear progression between the two controls.  
There were no biomaterials in these wells, which indicates that the control wells were not 
running out of materials on which they could grow.   
Test of peptide and protein:  Since cells were not limited on materials for growth, it 
can be deduced that the wells that with added biomaterials were also not running out of 
fuel on which they could grow, because even the control wells that contained no cellular 
growth medium were still growing at all time periods.  With that being said, it is evident 
that the biomaterials that are added to the testing wells are essentially used up fairly 
quickly within the four to six hour marks.  Then, the cells return to a normal and stable 
growth phase where the growth is almost equal to the amount of cellular growth with no 
added biomaterials.   
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Long-term toxicity experiments showed much more overall growth of cells, and the 
test wells far exceeded the negative controls.  This observation is consistent with the 
interpretation that added serum/protein/peptide promotes growth of cells overall. The 
limitation of these experiments is that it is impossible to parse whether there is a 
contribution from the added protein/peptide or not.  In future studies, we should add an 
additional control well with serum added, but no test materials. 
Failure to Express PCLP 
The PCLP construct that is laid out in Figure 1 was never correctly expressed.  While 
the CCLP construct was correctly expressed and purified, several different attempts to 
purify the PCLP construct designed by the Pedigo lab never came to fruition.  While we 
do not fully understand what is causing the problem, we speculate that two things might 
be inhibiting the success of this experiment.  Firstly, the protein was not expressed at 
levels that this expression usually affords. We are not sure what the problem is, and in 
fact, the problems varied with each successive attempt. Poor expression may be due to 
secondary or tertiary folding of the construct as it rolls off the ribosome that leads to 
premature termination of translation.  Secondly, there are multiple hydrophobic residues 
contained within the PCLP construct that might cause the peptide to fold inwards upon 
itself, burying the His6 affinity label.  Because of this, the PCLP would not purify 
correctly during the His-Tag purification process.   
Dilution of Protein Concentrations 
The concentration of biomaterials that are being tested in these two assays is very 
low.  The working concentrations of 2 µM, 0.2µM, and 0.02 µM that were tested in these 
experiments were relatively small, compared to other studies that have been performed 
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by Jing and others in the past [29].  Being that the concentration of our biomaterials is so 
small, the nature of the media in which we use for the trials was very important.  For the 
intermediate toxicity assay, I worked with Dr. Khan to devise an experiment that would 
allow for maximum interaction of our biomaterials with the HEPG2 cells.  The problem 
that I aimed to address was minimizing interactions of our protein and peptide with the 
serum proteins and various additives that are often added to growth media.  I wanted our 
biomaterials to be the only thing in contact with the cells during the assay. The solution 
that we came up with was the short-term exposure assay, which I have entitled 
intermediate toxicity assay.  This assay used a media that was not substituted with any 
serum and contained no other proteins or peptides that could interfere with our 
biomaterials to dilute their affects upon the cells.  While this allowed for our biomaterials 
to take the center stage in the assay, we believe it inhibited the growth of cells in the 
assay.  While there was overall growth over the 8 hour time frame, it was attenuated in 
comparison to the 24 hour study.  While most MTT assays are run over the course of 24 
hours to several days, this intermediate toxicity assay was limited by the fact that the cells 
were not contained in any serum-substituted media that would allow for them to grow.  
The Importance of MTT and Cell Count 
It is important to discuss the role of the MTT reagent in the cytotoxicity assay.  MTT 
is the sole reagent used in the assay.  The addition of MTT to the wells puts the cells into 
stasis and allows for them to be assessed for viability.  When the MTT is added to each of 
the wells, it uses the NADH that is produced by the mitochondria and the MTT is 
converted into the formazan product.  The amount of MTT that is converted into 
formazan is what is measured by the microtitre plate reader; however, a parameter that 
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affects this greatly is the amount of cells that are contained within each well.  The rate of 
conversion of MTT to formazan is directly dependent upon the amount of NADH that is 
being produced by each cell within each well.  Therefore, making sure that each well has 
the exact same number of viable cells is crucial because the metabolic activity of each 
cell is being directly measured through the use of the MTT reagent.  While there is not a 
definite way to make sure that each well contains the exact same amount of cells, extreme 
care was taken to make sure that the cells were counted and aliquotted correctly.  The use 
of repeats, as seen in the long-term study, also minimized the chances for error and 
helped standardize the mean number of cells per well.   
In conclusion, this work was successful in many respects.  It establishes a working 
relationship with Dr.S. Khan allowing the Pedigo lab, thereby broadening the tools 
available for assessment of the biomaterials under development there. Secondly, these 
experiments will inform any future efforts along these lines.  The cell lines were and 
MTT technology seemed to work as planned.  We changed the growth media between the 
two experiments.  The take-home message there is that we should increase the 
cconcentration of the test materials and make sure that serum is present in the growth 
media for both the peptide/protein added test samples and a “negative”control. 
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